Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $19.71M (cash outflow) rose 81.0% year over year, ahead of the +40.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 12.3% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +81.0% holds above the trailing-twelve-month pace of +40.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (42.1M) USD
- Year-over-year change
- -10.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.1M) | -10.0% |
| FY2024 | 2024-12-31 | (38.29M) | -20.2% |
| FY2023 | 2023-12-31 | (31.85M) | -12.4% |
| FY2022 | 2022-12-31 | (28.33M) | +2.1% |
| FY2021 | 2021-12-31 | (28.95M) | — |
Free Cash Flow vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +40.1% is the 5th highest of 9, against a peer median of +42.5%.
- Over three fiscal years its annual growth of +14.1% compares with a peer median of +27.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $268.74M USD | +732.4% | — | 244.8% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 225.86M SEK | -31.6% | +7.4% | 16982.6% |
| LTM Jun 2026 | $174.39M USD | -6.8% | — | 15.3% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $140.01M USD | +68.1% | +91.1% | 4214.6% |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $80.71M USD | +16.8% | +192.3% | 403.5% |
| LTM Sep 2026 | $61.69M USD | +40.1% | +14.1% | — | |
| LTM Jun 2026 | $60.51M USD | +148.8% | +11.1% | 13.4% | |
| LTM Mar 2026 | $38.8M USD | -77.0% | -9.0% | 55.7% | |
| LTM Mar 2026 | $38.14M USD | +129.6% | +43.9% | — | |
| Peer median (excluding TRVI) | — | +42.5% | +27.5% | 244.8% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| Deferred Income Tax | (82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.54M | 2.33M | 2.25M | 3.59M | 5.19M |
| Change in Working Capital | 1.51M | (1.23M) | (3.85M) | 6.83M | (3.49M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 831K | 9K | (1.05M) | 1.61M | (598K) |
| Other Working Capital | 678K | (1.24M) | (2.8M) | 5.22M | (2.89M) |
| Other Non-Cash Items | 974K | (162K) | (1.17M) | (907K) | (1.17M) |
| Operating Cash Flow | (28.95M) | (28.18M) | (31.71M) | (38.26M) | (42.09M) |
| Capital Expenditures | 0 | (159K) | (137K) | (35K) | (12K) |
| Acquisitions (Net) | 0 | (829K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (126.22M) | (9.93M) | (98.46M) | (170.66M) |
| Sales of Investments | 0 | 19M | 69.5M | 75.6M | 74.93M |
| Other Investing Activities | 0 | 829K | 0 | 1.37M | 1.64M |
| Investing Cash Flow | 0 | (107.37M) | 59.43M | (21.53M) | (94.11M) |
| Debt Repayment | (68K) | (5.83M) | (9.41M) | (126K) | 0 |
| Common Stock Issued | 21.18M | 105.41M | 1.71M | 61.15M | 120.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (340K) | 11.73M | (211K) | 464K | 714K |
| Financing Cash Flow | 20.78M | 111.31M | (7.91M) | 61.48M | 121.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.17M) | (24.24M) | 19.81M | 1.7M | (15.18M) |
| Free Cash Flow | (28.95M) | (28.33M) | (31.85M) | (38.29M) | (42.1M) |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.